OKYO Pharma Limited operates as a life sciences and biopharmaceutical company in the United Kingdom. Its pre-clinical development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM8, a non-opioid analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.09    OTCQB
As of 01/25/2022     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Index country:  United Kingdom
Country of incorporation:  
IPO date:  12/23/2021
Outstanding shares:  970,686,108
Average volume:  0
Market cap:   $82,508,319
Current dividend yield:  0.00%
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   14.17
PS ratio:   0.00
Return on equity:   -511.10%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy